[HLBANK] QoQ Quarter Result on 31-Mar-2018 [#3]

Stock
[HLBANK] HONG LEONG BANK BHD
Announcement Date
30-May-2018
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2018
Quarter
31-Mar-2018 [#3]
Profit Trend
QoQ- 1.02%
YoY- 21.16%
Quarter Report
Latest QR
Upcoming QR
HLBANK's Result
HLBANK's Financial Summary
View:
Show?
Quarter Result
31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 CAGR
Revenue 1,142,170 1,249,025 1,176,314 1,256,066 1,228,555 1,178,630 1,151,918 -0.56%
PBT 823,201 851,135 777,638 855,126 833,099 780,392 679,959 13.55%
Tax -135,955 -144,220 -151,630 -165,095 -150,028 -141,424 -197,042 -21.86%
NP 687,246 706,915 626,008 690,031 683,071 638,968 482,917 26.43%
-
NP to SH 687,246 706,915 626,008 690,031 683,071 638,968 482,917 26.43%
-
Tax Rate 16.52% 16.94% 19.50% 19.31% 18.01% 18.12% 28.98% -
Total Cost 454,924 542,110 550,306 566,035 545,484 539,662 669,001 -22.61%
-
Net Worth 24,468,126 25,817,524 23,893,507 23,340,592 23,197,104 23,319,839 22,684,628 5.16%
Dividend
31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 CAGR
Div 327,332 - 654,616 - 327,296 - 613,650 -34.15%
Div Payout % 47.63% - 104.57% - 47.92% - 127.07% -
Equity
31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 CAGR
Net Worth 24,468,126 25,817,524 23,893,507 23,340,592 23,197,104 23,319,839 22,684,628 5.16%
NOSH 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 0.00%
Ratio Analysis
31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 CAGR
NP Margin 60.17% 56.60% 53.22% 54.94% 55.60% 54.21% 41.92% -
ROE 2.81% 2.74% 2.62% 2.96% 2.94% 2.74% 2.13% -
Per Share
31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 CAGR
RPS 55.83 57.62 57.50 61.40 60.06 57.62 56.31 -0.56%
EPS 33.59 34.55 30.60 33.73 33.39 31.24 23.61 26.41%
DPS 16.00 0.00 32.00 0.00 16.00 0.00 30.00 -34.15%
NAPS 11.96 11.91 11.68 11.41 11.34 11.40 11.09 5.14%
Adjusted Per Share Value based on latest NOSH - 2,167,718
31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 CAGR
RPS 55.72 60.93 57.38 61.27 59.93 57.50 56.19 -0.55%
EPS 33.53 34.48 30.54 33.66 33.32 31.17 23.56 26.44%
DPS 15.97 0.00 31.93 0.00 15.97 0.00 29.94 -34.15%
NAPS 11.936 12.5943 11.6557 11.386 11.316 11.3758 11.066 5.16%
Price Multiplier on Financial Quarter End Date
31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 CAGR
Date 31/12/18 28/09/18 29/06/18 30/03/18 29/12/17 29/09/17 30/06/17 -
Price 20.40 20.58 18.20 18.80 17.00 15.86 15.66 -
P/RPS 36.54 35.72 31.65 30.62 28.31 27.53 27.81 19.90%
P/EPS 60.73 63.11 59.47 55.73 50.91 50.77 66.33 -5.69%
EY 1.65 1.58 1.68 1.79 1.96 1.97 1.51 6.07%
DY 0.78 0.00 1.76 0.00 0.94 0.00 1.92 -45.05%
P/NAPS 1.71 1.73 1.56 1.65 1.50 1.39 1.41 13.68%
Price Multiplier on Announcement Date
31/12/18 30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 CAGR
Date 26/02/19 28/11/18 28/08/18 30/05/18 26/02/18 30/11/17 24/08/17 -
Price 21.30 20.70 20.00 18.60 18.52 15.14 15.50 -
P/RPS 38.15 35.93 34.78 30.29 30.84 26.28 27.52 24.25%
P/EPS 63.41 63.48 65.36 55.14 55.46 48.47 65.65 -2.28%
EY 1.58 1.58 1.53 1.81 1.80 2.06 1.52 2.60%
DY 0.75 0.00 1.60 0.00 0.86 0.00 1.94 -46.83%
P/NAPS 1.78 1.74 1.71 1.63 1.63 1.33 1.40 17.31%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment